$ARCT Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data. https://www.businesswire.com/news/home/20201228005277/en/Arcturus-Therapeutics-Received-Approval-from-Singapore-Health-Sciences-Authority-to-Proceed-with-Phase-2-Study-of-ARCT-021-LUNAR-COV19-Vaccine-Candidate-and-Provides-New-and-Updated-Clinical-and-Preclinical-Data